Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481281 | 1.00 | ADRB1 (0.84) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL22481182 | 0.91 | ADRB1 (1.00) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL22481240 | 0.91 | ADRB1 (1.00) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL22493400 | 0.91 | ADRB1 (1.00) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL22481139 | 0.88 | ADRB1 (0.78) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL22490270 | 0.88 | ADRB1 (0.78) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL22481192 | 0.83 | ADRB1 (0.71) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL22481290 | 0.82 | ADRB1 (0.69) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL24481374 | 0.82 | ADRB1 (0.69) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL24630880 | 0.80 | ADRB1 (0.67) | ADRB1HIF1ALMNAADRB2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20200308114-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308114-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRA2B, ADRB2, ADRB1 | ADRB1 3/4885HIF1A 3024/4885LMNA 764/4885 |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | ADRB1 5/4885HIF1A 701/4885LMNA 228/4885 |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | ADRB1 5/4885HIF1A 701/4885LMNA 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.